Literature DB >> 5814307

Increased lecithin synthesis during phagocytosis by normal leukocytes and by leukocytes of a patient with chronic granulomatous disease.

P Elsbach, D Zucker-Franklin, C Sansaricq.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 5814307     DOI: 10.1056/NEJM196906122802403

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  7 in total

1.  Chorioretinal lesions in familial chronic granulomatous disease of childhood.

Authors:  L J Martyn; H W Lischner; A J Pileggi; R D Harley
Journal:  Trans Am Ophthalmol Soc       Date:  1971

2.  The pathogenesis of experimental pulmonary aspergillosis. An ultrastructural study of alveolar macrophages after phagocytosis of a flavus spores in vivo.

Authors:  L P Merkow; S M Epstein; H Sidransky; E Verney; M Pardo
Journal:  Am J Pathol       Date:  1971-01       Impact factor: 4.307

3.  [Oxidative metabolism of phagocytes: physicochemical events and clinical relevance (author's transl)].

Authors:  L H Block; R Lüthy; W Siegenthaler
Journal:  Klin Wochenschr       Date:  1980-12-01

4.  The interaction in vitro between polymorphonuclear leukocytes and mycoplasma.

Authors:  M S Simberkoff; P Elsbach
Journal:  J Exp Med       Date:  1971-12-01       Impact factor: 14.307

5.  Remodeling of granulocyte membrane fatty acids during phagocytosis.

Authors:  J E Smolen; S B Shohet
Journal:  J Clin Invest       Date:  1974-03       Impact factor: 14.808

6.  The appearance of lecithin- 32 P, synthesized from lysolecithin- 32 P, in phagosomes of polymorphonuclear leukocytes.

Authors:  P Elsbach; P Patriarca; P Pettis; T P Stossel; R J Mason; M Vaughan
Journal:  J Clin Invest       Date:  1972-07       Impact factor: 14.808

7.  The effects of the morphine analogue levorphanol on leukocytes. Metabolic effects at rest and during phagocytosis.

Authors:  N Wurster; P Elsbach; E J Simon; P Pettis; S Lebow
Journal:  J Clin Invest       Date:  1971-05       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.